Overview

• The UK government has signed a £1 billion partnership with BioNTech, backed by £129 million in public grants, to expand mRNA vaccine research and manufacturing.
• BioNTech will establish three research centers in Cambridge, London, and a yet-to-be-announced location, with the London hub specializing in AI-driven drug discovery.
• The initiative includes developing personalized cancer immunotherapies for 10,000 patients by 2030, leveraging mRNA technology and AI to tailor treatments to individual genetic profiles.
• The investment is expected to create hundreds of high-skilled jobs and reinforce the UK’s position as a global leader in life sciences innovation.
• This deal follows the UK’s 2022 mRNA partnership with Moderna and reflects lessons learned from a failed AstraZeneca investment earlier in 2025.